Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 4/2019

01-04-2019 | NSCLC | Guidelines

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing

Authors: Kumar Prabhash, Suresh H. Advani, Ullas Batra, Bivas Biswas, Anuradha Chougule, Mithua Ghosh, Vamshi Krishna Muddu, T. P. Sahoo, Ashok K. Vaid

Published in: Advances in Therapy | Issue 4/2019

Login to get access

Abstract

Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Indian clinical and pathology settings has been challenging due to operational and logistical constraints. This consensus guideline brings together medical oncologists, molecular pathologists and pathologists from India to provide a quick and competent reference for biomarker testing in NSCLC. The guideline summarizes the importance of targetable mutations in NSCLC such as epidermal growth factor receptor (EGFR), rearrangements in anaplastic lymphoma kinase and receptor tyrosine kinase encoded by ROS-1 gene, overexpression of programmed cell death ligand-1 and resistant EGFR mutations. It reaffirms recommendations from international working groups, discusses vulnerable pre-analytical procedures and provides a balanced review on the pros and cons of different diagnostic tests (immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction-based testing and next-generation sequencing). The document also provides an algorithm to aid diagnostic decision-making and a checklist to assess the quality of testing laboratories that will help the medical oncologists make an informed choice. Overall, these recommendations are based on evidence and clinical experience and will aid policymakers, oncologists, health care practitioners and pathologists who strive to implement molecular strategies and make informed decisions for improved care in NSCLC in India.
Funding: AstraZeneca Pharma India Limited.
Literature
1.
2.
Desai C, Mehta A, Mishra D. Usage patterns of biomarkers in non-small-cell lung cancer patients in India: findings from a systematic review and survey. Lung India. 2014;31(3):249–59.CrossRefPubMedPubMedCentral
3.
4.
5.
Nair C, Mathew A, George P. Lung cancer: presentation and pattern of care in a cancer center in South India. Indian J Cancer. 2017;54(1):164–8.CrossRefPubMed
6.
Shankar S, Thanasekaran V, Dhanasekar T, Duvooru P. Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India. Lung India. 2014;31(1):23–8.CrossRefPubMedPubMedCentral
7.
Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: following the global trend? Indian J Cancer. 2016;53(1):92–5.CrossRefPubMed
8.
Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2012;8(1):63–6.CrossRefPubMed
9.
Ho C, Tong KM, Ramsden K, Ionescu DN, Laskin J. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified. Curr Oncol. 2015;22(3):e164–70.CrossRefPubMedPubMedCentral
10.
Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29(28):3825–31.CrossRefPubMedPubMedCentral
11.
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–57.CrossRefPubMed
12.
D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–36.CrossRefPubMed
13.
Valdes M, Nicholas G, Goss GD, Wheatley-Price P. Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy. Curr Oncol. 2016;23(6):386–90.CrossRefPubMedPubMedCentral
14.
15.
Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thoracic Oncol. 2007;2(8):735–40.CrossRef
16.
17.
Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thoracic Oncol. 2015;10(5):768–77.CrossRef
18.
19.
Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014;4:204.CrossRefPubMedPubMedCentral
20.
Stanek L, Springer D, Konopasek B, et al. Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: a case report. Oncol Lett. 2017;14(6):7545–8.PubMedPubMedCentral
21.
Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 2017;18(6):359–68.CrossRefPubMedPubMedCentral
22.
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.CrossRefPubMed
23.
Tsao AS, Scagliotti GV, Bunn PA Jr, et al. Scientific advances in lung cancer 2015. J Thoracic Oncol. 2016;11(5):613–38.CrossRef
24.
Jett JR, Carr LL. Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med. 2013;188(8):907–12.CrossRefPubMed
25.
Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol. 2016;34(15_suppl):9017.CrossRef
26.
27.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMed
28.
Chandra S, Mohan A, Guleria R, Singh V, Yadav P. Delays during the diagnostic evaluation and treatment of lung cancer. Asian Pac J Cancer Prev. 2009;10(3):453–6.PubMed
29.
Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer Prev. 2009;10(3):335–8.PubMed
30.
Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–8.PubMedPubMedCentral
31.
Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015;26(7):1415–21.CrossRefPubMed
32.
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.CrossRefPubMed
33.
Chougule A, Prabhash K, Noronha V, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS ONE. 2013;8(10):e76164.CrossRefPubMedPubMedCentral
34.
Doval D, Prabhash K, Patil S, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Therapy. 2015;8:117–23.PubMedPubMedCentral
35.
Aggarwal S, Patil S, Minhans S, Pungliya M, Soumitra N. A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Clin Oncol. 2012;30(15):e18041–e18041.
36.
Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thoracic Oncol. 2014;9(2):154–62.CrossRef
37.
Joshi A, Zanwar S, Noronha V, et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? OncoTargets Therapy. 2017;10:1859–63.CrossRefPubMedPubMedCentral
38.
Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.CrossRefPubMed
39.
Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceut Sinica B. 2015;5(5):390–401.CrossRef
40.
Singh N, Vishwanath G, Aggarwal AN, Behera D. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash. Indian J Chest Dis Allied Sci. 2014;56(3):149–52.PubMed
41.
Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: a clinical perspective and review of published literature. World J Clin Oncol. 2014;5(5):858–64.CrossRefPubMedPubMedCentral
42.
Bhatt AD, Pai R, Rebekah G, et al. Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status. Indian J Cancer. 2013;50(2):94–101.CrossRefPubMed
43.
Noronha V, Prabhash K, Thavamani A, et al. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS ONE. 2013;8(4):e61561.CrossRefPubMedPubMedCentral
44.
Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer. 2013;50(2):80–6.CrossRefPubMed
45.
Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–70.CrossRefPubMed
46.
Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncol. 2013;8(1):55–67.CrossRef
47.
Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (Oxford, England: 1990). 2010;46(10):1773–80.CrossRef
48.
Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.CrossRefPubMed
49.
Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–46.CrossRefPubMed
50.
Noronha V, Chandrakanth MV, Joshi AP, et al. ROS1 rearranged nonsmall cell lung cancer and crizotinib: an Indian experience. Indian J Cancer. 2017;54(2):436–8.CrossRefPubMed
51.
Noronha V, Ramaswamy A, Patil VM, et al. ALK positive lung cancer: clinical profile, practice and outcomes in a developing country. PLoS ONE. 2016;11(9):e0160752.CrossRefPubMedPubMedCentral
52.
Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2018;25(Suppl 1):S103–14.CrossRefPubMedPubMedCentral
53.
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRefPubMedPubMedCentral
54.
55.
56.
Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499–506.CrossRefPubMed
57.
Vallonthaiel AG, Malik PS, Singh V, et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol. 2017;31:56–61.CrossRefPubMed
58.
Veldore VH, Patil S, Satheesh CT, et al. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: an effort to explore new drug targets. Indian J Cancer. 2015;52(2):243–8.CrossRefPubMed
59.
Jacob LA, Lakshmaiah K, Govindbabu K, et al. Genomic profiling of non-small cell lung cancer: a pilot study from South India. Int J Mol Immuno Oncol. 2017;2(2):63–6.CrossRef
60.
Thungappa S, Patil S, Shashidhara H, et al. P2. 03b-064 genomic profiling in non-small cell lung cancer: new hope for personalized medicine: topic: biomarkers. J Thoracic Oncol. 2017;12(1):974–5.CrossRef
61.
Pathak A, Rajappa S, Gore A. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Indian J Cancer. 2017;54(Supplement):S1–8.CrossRefPubMed
62.
Weart TC, Miller KD, Simone CB 2nd. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer Manag Res. 2018;10:647–52.CrossRefPubMedPubMedCentral
63.
Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984–93.CrossRefPubMedPubMedCentral
64.
Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–90.CrossRefPubMed
65.
Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thoracic Oncol. 2013;8(7):823–59.CrossRef
66.
Garrido P, de Castro J, Concha A, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Trans Oncol. 2012;14(5):338–349.
67.
Iding JS, Krimsky W, Browning R. Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies. J Thoracic Dis. 2016;8(Suppl 6):S488–93.CrossRef
68.
Hu YC, Zhang Q, Huang YH, Liu YF, Chen HL. Comparison of two methods to extract DNA from formalin-fixed, paraffin-embedded tissues and their impact on EGFR mutation detection in non-small cell lung carcinoma. Asian Pac J Cancer Prev. 2014;15(6):2733–7.CrossRefPubMed
69.
Muley TR, Herth FJ, Schnabel PA, Dienemann H, Meister M. From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience. Transl Lung Cancer Res. 2012;1(2):111–21.PubMedPubMedCentral
70.
Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71(2):177–84.CrossRefPubMed
71.
Raja T, Warrier N. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(5):9–14.CrossRef
72.
Warth A, Penzel R, Brandt R, et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch. 2012;460(4):407–14.CrossRefPubMed
73.
O’Donnell P, Ferguson J, Shyu J, et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013;13:210.CrossRefPubMedPubMedCentral
74.
Prabhash K, Parikh PM, Noronha V, et al. Patterns of EGFR testing for lung cancer among tertiary care centers in India. J Clin Oncol. 2015;33(15_suppl):e19114–e19114.
75.
Raja T, Warrier NK. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(Supplement):S9–14.CrossRefPubMed
76.
Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017;2(1):e000168.CrossRefPubMedPubMedCentral
77.
Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer (Amsterdam, Netherlands). 2011;73(3):316–9.CrossRef
78.
Veldore V, Rao R, Kakara S, et al. Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer. 2013;50(2):87–93.CrossRefPubMed
79.
Young EC, Owens MM, Adebiyi I, et al. A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol. 2013;22(4):190–5.CrossRefPubMed
80.
Prabhash K, Parikh PM, Rajappa SJ, et al. EGFR testing scenario across 111 centres in India: a questionnaire-based survey. J Clin Oncol. 2017;35(15_suppl):e13111–e13111.
81.
Pauwels P, Remmelink M, Hoton D, et al. Pathological diagnosis and molecular testing in non-small cell lung cancer: belgian guidelines. Belg J Med Oncol. 2016;10(4):123–31.
82.
Singh R, Rohtagi N. Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India. S Asian J Cancer. 2017;6(4):171–5.CrossRef
83.
Chatterjee K, Bhowmik R, Chattopadhyay B. Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: using immunohistochemistry as the diagnostic modality in a significant subset. S Asian J Cancer. 2017;6(4):169–70.CrossRef
84.
Bal A, Singh N, Agarwal P, Das A, Behera D. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. APMIS. 2016;124(10):832–8.CrossRefPubMed
85.
Wagle PB, Jambhekar NA, Kumar R, et al. A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: a search for a testing algorithm. Indian J Cancer. 2017;54(1):148–54.CrossRefPubMed
86.
Batra U, Aggarwal M, Jain P, et al. Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung. South Asian J Cancer. 2018;7(1):61–4.PubMedPubMedCentral
87.
Joshua JM, Salima K, Pavithran K, Vijayan M. Crizotinib, an effective agent in ROS1-rearranged adenocarcinoma of lungs: a case report.Clinical medicine insights. Case Rep. 2018;11:1179547617749615.
88.
Suryavanshi M, Panigrahi MK, Kumar D, et al. ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India. 2017;34(5):411–4.PubMedPubMedCentral
89.
Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12.CrossRefPubMedPubMedCentral
90.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed
91.
Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol. 2011;2011:165214CrossRefPubMedPubMedCentral
92.
Advani S, Malhotra H, Chacko R, et al. Advanced therapeutic options and importance of repeat biopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: an expert opinion. Indian J Cancer. 2017;54(5):31–6.CrossRef
93.
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26–75ra26.
94.
Ji W, Choi C-M, Rho JK, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013;13(1):606.CrossRefPubMedPubMedCentral
95.
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–7.CrossRefPubMedPubMedCentral
96.
Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–289.
97.
Ercan D, Choi HG, Yun C-H, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21(17):3913–23.CrossRefPubMedPubMedCentral
98.
Stewart EL, Tan SZ, Liu G, Tsao M-S. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res. 2015;4(1):67.PubMedPubMedCentral
99.
Li H, Hu H, Wang R, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. OncoTargets Therapy. 2014;7:513.CrossRefPubMedPubMedCentral
100.
Su K-Y, Chen H-Y, Li K-C, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–40.CrossRefPubMed
101.
Chougule A, Basak S. Epidermal growth factor receptor T790M testing in progressed lung cancer: a review of sensitive methods for analysis of tissue and liquid biopsy samples. Indian J Cancer. 2017;54(5):45–54.CrossRef
102.
Zanwar S, Noronha V, Joshi A, et al. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: feasibility, limitations, and clinical utility in Indian patients. Indian J Cancer. 2017;54(1):280–4.CrossRefPubMed
103.
Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.CrossRefPubMed
104.
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–40.CrossRefPubMed
105.
Ricciuti B, Chiari R, Chiarini P, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig. 2016;36(8):683–6.CrossRefPubMed
106.
John T, Bowden JJ, Clarke S, et al. Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pac J Clin Oncol. 2017;13(4):296–303.CrossRefPubMed
107.
Zarogoulidis P, Gaga M, Huang H, Darwiche K, Rapti A, Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med. 2017;6:6.
108.
Campo M, Gerber D, Gainor JF, et al. Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies. J Thoracic Oncol. 2016;11(11):2022–6.CrossRef
109.
110.
Wu YL, Sequist LV, Hu CP, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017;116(2):175–85.CrossRefPubMed
111.
112.
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.CrossRefPubMed
113.
De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.CrossRefPubMedPubMedCentral
114.
Warton K, Yuwono NL, Cowley MJ, McCabe MJ, So A, Ford CE. Evaluation of streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther. 2017;21(5):563–70.CrossRefPubMed
115.
Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ. Circumventing qPCR inhibition to amplify miRNAs in plasma. Biomark Res. 2014;2:13.CrossRefPubMedPubMedCentral
116.
Veldore VH, Choughule A, Routhu T, et al. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. Lung Cancer (Auckland, N.Z.). 2018;9:1–11.
117.
Chatterjee K, Ray A, Chattopadhyay B. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): a report of 106 patients from Kolkata. Indian J Cancer. 2017;54(1):305–7.CrossRefPubMed
118.
Sheikine Y, Rangachari D, McDonald DC, et al. EGFR testing in advanced non-small-cell lung cancer. A mini-review. Clin Lung Cancer. 2016;17(6):483–92.CrossRefPubMed
119.
Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8(7):12501–16.CrossRefPubMed
120.
Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clin Cancer Res. 2011;17(5):1169–80.CrossRefPubMedPubMedCentral
121.
Zhao J, Feng H, Zhao J, et al. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett. 2016;11(4):2573–9.CrossRefPubMedPubMedCentral
122.
Shao D, Lin Y, Liu J, et al. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Sci Rep. 2016;6:22338.CrossRefPubMedPubMedCentral
123.
Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–15.CrossRefPubMed
Metadata
Title
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing
Authors
Kumar Prabhash
Suresh H. Advani
Ullas Batra
Bivas Biswas
Anuradha Chougule
Mithua Ghosh
Vamshi Krishna Muddu
T. P. Sahoo
Ashok K. Vaid
Publication date
01-04-2019
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 4/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-00903-y

Other articles of this Issue 4/2019

Advances in Therapy 4/2019 Go to the issue

Brief Report

Case Series of Combined iStent Implantation and Phacoemulsification in Eyes with Primary Angle Closure Disease: One-Year Outcomes

Commentary

The Progressive Multifocal Leukoencephalopathy Consortium as a Model for Advancing Research and Dialogue on Rare Severe Adverse Drug Reactions

Review

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia

Brief Report

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD

Brief Report

Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study

Original Research

Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits